Esperion Therapeutics ESPR Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's retained earnings?
- Esperion Therapeutics (ESPR) reported retained earnings of -$1.65B in Q1 2026.
- How has Esperion Therapeutics's retained earnings changed year-over-year?
- Esperion Therapeutics's retained earnings decreased by 0.5% year-over-year, from -$1.64B to -$1.65B.
- What is the long-term trend for Esperion Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Esperion Therapeutics's retained earnings has grown at a 14.1% compound annual growth rate (CAGR), from -$838.82M to -$1.62B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.